SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards, sparking debates about a potential data center bubble and the stock's valuation following a deal with Microsoft. Community members are actively discussing institutional buying versus retail bearishness, with some suggesting market manipulation and others anticipating a bounce. Overall sentiment is mixed, with some seeing the dip as a buying opportunity and others expressing concerns about further declines.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group N.V. ($NBIS) is trending amid overnight trading volatility and a broader selloff in AI-related stocks, leading to community discussions about potential bottom levels and future price movement. Investors are weighing the impact of recent deals with Microsoft and Meta against concerns about dilution and overall market sentiment, while some speculate about potential Nasdaq 100 inclusion and its effect on buying pressure. Discussions also mention Michael Burry closing his hedge fund, with some seeing this as a bullish signal.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending as the stock experiences significant volatility, driven by investor reactions to a recent $2.35 billion senior secured notes offering and broader concerns about an AI bubble. While some investors express worry about the debt and potential dilution, others view it as a necessary step for scaling and highlight the company's substantial contracts. Community discussions revolve around dip-buying strategies, long-term conviction in the AI data center space, and speculation regarding potential analyst upgrades or hyperscaler announcements.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor (OPEN) is trending amidst discussions around warrant issuance and its potential impact on the stock. The community is debating whether recent price action is a manipulation tactic by shorts or a buying opportunity for long-term holders, while some express concerns over dilution. Despite market headwinds, OPEN is showing relative strength, fueling speculation about a potential short squeeze and a climb to double digits.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors discuss an insider buying over $2 million worth of shares, signaling confidence in the company. Community members are also closely watching for potential upcoming catalysts like LTV and CLPS contract announcements, with some speculating on a potential LTV contract win. Overall sentiment suggests bullishness based on the company's potential and oversold conditions in the small-cap market.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss its future amid government interest in securing critical mineral supply chains, with some highlighting the company's attendance at the Underwater Minerals Conference. Community members are analyzing recent earnings, potential government partnerships, and NOAA approval timelines as key catalysts. The stock is also being discussed in relation to broader movements in the rare earth and critical minerals sector, with some anticipating a significant price increase.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors await a decision on its Alzheimer's drug, Blarcamesine, from the European Medicines Agency (EMA). The community is buzzing with anticipation, with some expressing concerns about potential leaks and others highlighting positive data and the drug's safety profile. Discussions also involve commentary from controversial figures, adding to the volatility and uncertainty surrounding the stock.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending due to concerns and disappointment surrounding lowered FY2025 sales guidance, despite a revenue beat in Q3. The community is discussing the credibility of management, potential impacts of government shutdowns on contracts, and comparing RCAT's performance to sector peers like ONDS. Some investors view the pullback as a buying opportunity, citing long-term potential in drone and maritime unmanned systems within the defense sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending downwards, with community members pointing to concerns about the approval of Elon Musk's pay package and its potential impact on the stock's stability. Some traders are also discussing the company's future prospects, competition in the EV sector, and potential price targets. Others are noting the broader market downturn and its effect on Tesla's performance.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Round Rock, TX.

TSS Inc

TSSI is trending due to a significant after-hours drop following disappointing earnings, with revenue down 40% and a net loss reported. The community is debating the reasons behind the poor performance, citing factors like lower procurement revenues, facility upgrade disruptions, and concerns about the company's relationship with Dell. Despite the negative reaction, some investors remain optimistic, pointing to the company's long-term growth potential and increased capacity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Omeros Corporation Reports Third Quarter 2025 Financial Results

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2025, which include: Net loss for the third...

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025, after the market closes...

Weekly Stock Market Update: Apple, Taiwan Semiconductor and Novo Nordisk

It was a volatile but ultimately positive week on Wall Street, marked by renewed tensions in the U.S.-China trade war and a strong start to the earnings season. Major banks exceeded expectations...

NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio

Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing survival outcomes in...

Omeros’ stock had&nbsp;its best day on Wednesday ever after H.C. Wainwright raised its price target to $20 from $9 and kept a ‘Buy’ rating, following news of a multibillion-dollar licensing deal with Novo Nordisk for its rare disease drug candidate zaltenibart.<a href="https://stocktwits.com/symbol/OMER">Shares of Omeros</a> jumped 154.1% to close at $10.42 on Wednesday, before slipping 3.1% in after-hours trading, while&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed shares</a> edged up 0.1% to $54.06.The brokerage said Omeros will get $240 million upfront, along with up to $510 million in development and approval milestone payments and as much as $1.3 billion tied to future sales, plus royalties. H.C. Wainwright said the new target reflects the significant non-dilutive cash Omeros will receive and updated risk assumptions for zaltenibart.Under the agreement, Novo Nordisk will take full global control of developing and commercializing zaltenibart, which targets MASP-3, a key protein linked to several rare blood and kidney disorders. The deal could be worth as much as $2.1 billion if all milestones are met. Novo Nordisk said the medicine could become a best-in-class option and will help strengthen its rare disease business.Omeros CEO Gregory Demopulos said teaming up with Novo Nordisk allows the drugmaker to expand zaltenibart’s reach worldwide while Omeros focuses on bringing its own drug, narsoplimab, to market.&nbsp;Novo Nordisk said it plans to start a global phase 3 study of zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH) and explore its use in other rare conditions. The deal is expected to close by late 2025.On Stocktwits, retail sentiment for Omeros was ‘extremely bullish’ amid ‘extremely high’ message volume, while sentiment for Novo Nordisk was ‘extremely bearish’ with ‘low’ message volume.One user on Stocktwits said the royalties from the Novo Nordisk deal alone could be worth billions, adding that despite some short-seller claims, Omeros still has an impressive pipeline and plenty of funding to develop new drugs.&nbsp;<stembedurl>https://stocktwits.com/whatsgood75/message/632507728</stembedurl>Another user said they had done their own research and believe the company is waiting on FDA decisions for other promising treatments, calling Omeros a solid firm with multiple revenue streams and saying they plan to buy more shares.<stembedurl>https://stocktwits.com/SnoddyTradz/message/632496306</stembedurl>While Omeros’ stock has risen 5% so far in 202, Novo Nordisk’s U.S.-listed stock has declined 33% over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside

The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart.

Equity

Danish drugmaker Novo Nordisk (NVO) on Wednesday said that it has entered into a definitive asset purchase and license agreement with Omeros Corporation (OMER) for its drug candidate Zaltenibart.Zaltenibart is in clinical development for rare blood and kidney disorders. Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916434">deal,</a> Novo Nordisk will be granted exclusive global rights to develop and commercialize Zaltenibart in all indications.Omeros will receive $340 million in upfront and near-term milestone payments and will be eligible to receive up to a total of $2.1 billion, including commercial milestone payments, in addition to tiered royalties on net sales. Following the closing of the transaction, Novo intends to initiate a global late-stage program for Zaltenibart in paroxysmal nocturnal hemoglobinuria, a rare, acquired blood disorder where the body's immune system mistakenly attacks and destroys red blood cells. Omeros has already reported positive mid-stage data for Zaltenibart in treating the blood disorder.The transaction is expected to close in the fourth quarter of 2025. <a href="https://stocktwits.com/symbol/OMER">OMER shares</a> soared 136% in the pre-market session. On Stocktwits, retail sentiment around OMER jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.“Novo Nordisk is in a strong position to build on the work done by Omeros to maximize the value of this asset and develop Zaltenibart into a differentiated and potentially best-in-class treatment approach for a number of rare blood and kidney disorders,” said Martin Holst Lange, chief scientific officer and executive vice president of Research &amp; Development at Novo Nordisk.Omeros CEO Gregory A. Demopulos said that the company will now focus on securing approval and commercialization of Narsoplimab this quarter for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Novo, meanwhile, will also explore further development of Zaltenibart in a range of other rare blood and kidney disorders.OMER stock rose 7% this year, while NVO shares dropped 34%.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-oral-glp-1-drug-reduced-blood-sugar-levels-in-two-late-stage-trials/ch6nxr4R3Nm">Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder

Under the deal, Omeros will receive $340 million in upfront and near-term milestone payments and will be eligible to receive up to a total of $2.1 billion, including commercial milestone payments.

Under the deal, Omeros will receive $340 million in upfront and near-term milestone payments and will be eligible to receive up to a total of $2.1 billion, including commercial milestone payments, in addition to tiered royalties on net sales.

Omeros Corporation has filed a marketing authorization application (MAA) with the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).The MAA is based on response-evaluable analyses of patients treated with narsoplimab and a comparison of overall survival with a well-matched external control group.&nbsp;According to the company, the submission shows a 61% response rate and a three-fold improvement in overall survival in the narsoplimab cohort.&nbsp;It also incorporates outcomes from over 130 patients treated under Omeros’ expanded access program.Following the news, H.C. Wainwright reiterated a ‘Buy’ rating and $9 price target on the stock.&nbsp;Analyst Brandon Folkes wrote that the EMA submission supports the view that Omeros “may be entering a phase of rerating” over the next 12 months, driven by potential U.S. approval, EU approval, and renewed appreciation for the broader pipeline.&nbsp;The firm expects narsoplimab to secure regulatory clearance in both regions, creating “significant value” for the company.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.Retail investors voiced concerns after Omeros Corporation’s June 27 shareholder meeting, during which audio reportedly cut out during two critical questions on the company's regulatory outlook.One user claimed that approximately 80 seconds of the meeting, covering responses to questions about the status of the biologics license application (BLA) and the FDA’s ability to meet its PDUFA timeline, were missing from both the live broadcast and its replay.&nbsp;<stembedurl>https://stocktwits.com/WinstonWolfff/message/619393411</stembedurl>“We, as shareholders, deserve to hear the complete responses,” they wrote, adding that Omeros has “a HUGE shareholder relations/communication problem.”Another investor said they emailed Omeros directly, describing the audio loss during the “most important two questions regarding FDA approval” as “beyond embarrassing.”&nbsp;<stembedurl>https://stocktwits.com/TRYII/message/619392905</stembedurl>The user called for a full update and transcript, writing: “Please do the right thing here… Many, many investors are asking and suspicious.”<a href="https://stocktwits.com/symbol/OMER">Omeros'</a> stock has declined 67.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Omeros Seeks EMA Approval For Narsoplimab After Data Shows 3X Survival Boost

The application includes outcomes from more than 130 patients treated under an expanded access program, supporting broader regulatory momentum for narsoplimab. 

Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros first-in-class monoclonal antibody inhibiting the...

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

$IONQ

$RGTI

$QBTS

$QUBT

Are you buying the dip on any of these quantum stocks? 
 
If no, drop a comment.

Current Price	$6.28
Prev Close	$6.89
Open	$6.84
Dividend Yield	0.00%
50-Day Moving Average	$5.71
Beta	1.38
Avg. Volume	7.38M
PE Ratio	-2.98

52-Week High	$13.60
52-Week Low	$2.95
Market Capitalization	$468.9M
EPS (Annual)	-$2.70
Price to Book	-1.65
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

OMER
Omeros Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OMER News

OMEROmeros Corporation